Fig. 7: USP7 inhibition during the pancreatic progenitor and endocrine maturation stages of iPSC-to-beta-cell differentiation does not impact INS+ beta-like cell generation.

a Schematic of the adapted differentiation protocol, with or without GNE-6640 treatment during the pancreatic progenitor (D0–D5), endocrine progenitor (D5–D12), or maturation stage (D12–D16). This diagram is adapted from ref. ⁵⁷ Fig. 1a, d under Public License CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/legalcode). b NGN3 (red) immunofluorescent staining in control and GNE-6640-treated samples at D12. The scale bar is 50 μm. c Quantification of NGN3⁺ cells in D12 control and GNE-6640-treated samples. The bar graph represents mean ± SEM, and statistical significance was determined by one-way ANOVA with the Dunnett post hoc test (n = 4 biologically independent experiments). d Immunofluorescent staining for INS, GCG, and SST in D16 control and GNE-6640-treated samples. The scale bar is 50 μm. e Quantification of INS+, GCG+, and SST+ cells in control and GNE-6640-treated samples. The bar graph represents mean ± SEM, and statistical significance was determined by one-way ANOVA with the Dunnett post hoc test (n = 4 biologically independent experiments). Source data are provided as a Source Data file.